Please assess the completion status of the following clinical trial:

Trial Title: A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LFC ≥10% as assessed by MRI-PDFF at time of screening.~* Body Mass Index (BMI) ≥25 kg/m² and ≤50 kg/m² at time of screening.~* Stable weight (based on self-reporting) defined as ≤5% gain or loss of body weight for at least 3 months before screening visit.~* No history of Type 2 Diabetes Mellitus (T2DM) OR history of T2DM with an Glycated Hemoglobin (A1C) ≤8.5% at screening AND controlled by diet or a stable dose of metformin for the 3 months before screening.~* A female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP), or is a WOCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 5 weeks after the last dose of study intervention.~* Participants in Taiwan are eligible between the ages of 20 to 70 years of age (inclusive).~* Participants in South Korea are eligible between the ages of 19 to 70 years of age (inclusive).~Exclusion Criteria:~* History of Type 1 Diabetes Mellitus (T1DM), diabetic ketoacidosis, or diabetes secondary to pancreatitis or pancreatectomy.~* Ongoing, inadequately controlled hypothyroidism or hyperthyroidism.~* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasm type-2 syndrome.~* Recent event (within 6 months prior to screening) of congestive heart failure, unstable angina, myocardial infarction, arterial revascularization, stroke, or transient ischemic attack.~* History or evidence of chronic liver disease other than NAFLD or Non-Alcoholic SteatoHepatitis (NASH).~* Known history of cirrhosis.~* History of acute or chronic pancreatitis.~* History of a bariatric surgical procedure or a known clinically significant gastric emptying abnormality.~* History of malignancy ≤5 years prior to screening, except for skin cancer or cervical cancer.~* Clinically active hematologic disorder.~* Diagnosis of human immunodeficiency virus (HIV).~* Surgery requiring general anesthesia within 3 months before screening visit.~* History of organ transplantation, except for corneal transplant.~* Active diabetic proliferative retinopathy or a history of maculopathy.~* Untreated obstructive sleep apnea.~* History of treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist within 6 months before screening.~* History of treatment with thiazolidinediones (ie, pioglitazone, rosiglitazone) within 6 months before screening.~* Previous use (within 3 months before screening) or current use of prescription weight-management medications or over-the-counter weight-loss medications or therapies.~* Treatment with systemic corticosteroid medication within 3 months before screening.~* Current treatment with anticoagulants (eg, warfarin, heparin).~* Inability to have an MRI-PDFF performed due to either severe claustrophobia, metallic implant that prevents MRI-PDFF examination, or any other contraindication to MRI-PDFF examination.~* Previous or current history of significant alcohol consumption (average of 7 standard drinks per week in females or 14 standard drinks per week in males) for a period of more than 3 consecutive months in the 24 months before screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Efinopegdutide (Type: EXPERIMENTAL): Efinopegdutide 20 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 2.4 mg from day 1 to week 3, 5.0 mg from week 4 to 7, and 10.0 mg from week 8 to 24.
- Semaglutide (Type: ACTIVE_COMPARATOR): Semaglutide 1.34 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 0.25 mg from day 1 to week 3, 0.5 mg from week 4 to 7, and 1.0 mg from week 8 to 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).